The FDA lifts a partial clinical hold on the Friedreich Ataxia Nomlabofusp Program.

Published Date: 23 May 2024

In the fourth quarter of 2024, Larimar Therapeutics plans to release preliminary findings from the open label extension study evaluating nomlabofusp in patients suffering from Friedreich Ataxia.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot